Month: December 2020

Press releaseMalmö, Sweden December 9, 2020Acarix announces the last patient included in Dan-NICAD II studyAfter the inclusion of 1726 patients, Acarix announces that the last patient has been included in Dan-NICAD II, a study of non-invasive diagnostic testing in patients with suspected Coronary Artery Disease (CAD).The Dan-NICAD II, including 1726 patients referred to coronary CT with symptoms suggestive of stable CAD from four hospitals in Denmark, was initiated in January 2018 to further establish the diagnostic accuracy of the CADScor®System compared to other stratification alternatives commonly used today in parallel with securing more validated clinical data for further sophistication of the CADScor® Algorithm.Combining Dan-NICAD I and II, the CADScor® data has been collected on 3401 patients which facilitates significant substance...

PressmeddelandeMalmö, 9 december 2020Acarix AB meddelar att den sista patienten i Dan-NICAD II studien har inkluderatsEfter att ha inkluderat 1726 patienter meddelade idag Acarix att den sista patienten har inkluderats i Dan-NICAD II, en dansk studie om icke-invasiv diagnostisk testning av kranskärlssjukdom (CAD) II.Dan-NICAD II studien omfattar fyra sjukhus i Danmark och data från sammanlagt 1726 patienter vilka samtliga skickats vidare till kranskärlsröntgen efter bedömt symtom på stabil kranskärlssjukdom. Studien inleddes i januari 2018 med syfte att ytterligare befästa den diagnostiska noggrannheten för CADScor®Systemet jämfört med andra stratifieringsalternativ tillgängliga idag.Därutöver var syftet med studien att säkra mer validerad, klinisk data för ytterligare vidareutveckling av CADScor®-algoritmen.Det sammanvägda patientantalet...

HONG KONG , Dec. 09, 2020 (GLOBE NEWSWIRE) — NetDragon Websoft Holdings Limited (“NetDragon” or “the Company”, Hong Kong Stock Code: 777), a global leader in building internet communities, is pleased to announce that its subsidiary, Chivox Co.,Ltd., (“Chivox”), has launched a new English learning product for primary school education – Chivox Intelligent English Learning (驰声优学). It adopts OMO (Online-Merge-Offline) model and the company’s self-developed intelligent oral assessment technologies. Renowned teachers are invited to set assessment questions for the product, which focuses on nurturing listening and speaking skills. Together with the Chivox Intelligent English Learning Journal (“Chivox Journal”,《驰声优学报》), it provides teachers and students with both online and offline environments for teaching and learning.Catering...

TAINAN, Taiwan, Dec. 09, 2020 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced a collaboration with Edge Impulse that enables the rapid development and deployment of machine learning (ML) models on the Himax HX6537-A WE-I Plus AI processor and Google TensorFlow Lite for Microcontrollers framework, allowing low-power, memory-constrained, and remote edge devices to detect complex motion, recognize sounds and classify images at sub-mW power consumption. The AI vision and sensor fusion solution is ideal for predictive maintenance, condition monitoring, asset tracking, and occupancy detection applications where power efficiency, bandwidth optimization and privacy are key requirements.“Himax and Edge Impulse...

WASHINGTON, Dec. 09, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced continued global investment in its Data & Analytics practice within the Forensic and Litigation Consulting segment with the appointment of Richard Chalk and Yuval Saban as Senior Managing Directors.Mr. Chalk, who is based in London, is a recognized expert providing data and analytics advice around business-critical events. These include financial crime and compliance investigations, litigation, valuation disputes, and other distressed circumstances. He drives the use of innovative technology and analytics to resolve some of the most complex issues challenging FTI Consulting’s clients. His main areas of expertise include complex data analytics and large-scale sanctions/anti-money laundering (“AML”) investigations, where he has represented...

The CLI study is unlikely to meet its primary endpoint by the time of the final analysisSubstantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpointPLX-PAD was well tolerated, and no safety concerns were raisedCompany to terminate the CLI study to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar yearCompany will host conference call on December 9, 2020, at 8:30 AM ET / 3:30 PM Israel timeHAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, today announced that the independent Data Monitoring Committee (DMC) of its global pivotal...

PRESS RELEASE9 December 2020Initiation of written procedure for BidCo af 28.04.2017 A/SOn 16 October 2019, BidCo af 28.04.2017 A/S (the “Company“) issued EUR 50,000,000 senior secured floating rate bonds due 2024 with ISIN SE0013234325 (the “Bonds“).In accordance with the terms and conditions for the Bonds, the Company has on the date hereof given instructions to Nordic Trustee & Agency AB (publ) (the “Agent“), being the agent under the Bonds to initiate a written procedure in order to request that the bondholders vote in favour of certain amendments, waivers and consents in respect of the terms and conditions of the Bonds.The notice of the written procedure and the proposed amendments, waivers and consents are available at the Company’s website (www.ssgbidco.com), and the purpose of such is...

SHANGHAI, China, Dec. 09, 2020 (GLOBE NEWSWIRE) — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC).EVER-132-002 is a Phase 3 Asian study designed to assess and compare the efficacy and safety of sacituzumab govitecan versus TPC in Asian patients with HR+/HER2- mBC who received at least two, and no more than four...